A treatment switching adjustment involves procedures used to estimate the effect of the originally randomized therapy on overall survival when individuals from the control group switch to the investigational therapy after progression. The intention-to-treat comparison remains valid for the effect of an allocation strategy, but it can attenuate the difference in overall survival because a portion of the control group receives the investigational therapy. Rank Preserving Structural Failure Time Model, Inverse Probability of Censoring Weighting, and two-stage procedures aim for an explicitly hypothetical contrast. <\/p>\n
In oncology parallel-group trials, the protocol may allow a control patient access to the investigational therapy after radiological progression. If this therapy influences survival, the survival curve of the control arm later contains effects of both regimens. An unadjusted ITT comparison then answers the question regarding the effect of the initial allocation, including the possibility of a later switch, rather than the question of survival without switching. <\/p>\n
An adjustment is only meaningful if this specific second clinical question is relevant for benefit-risk assessment or health economic modeling. It must not be used to retrospectively replace an undesirable ITT result. The target contrast, the permitted switching rule, the definition of progression, and the timing of the data cut-off should therefore already be included in the study protocol and in the definition of the estimand. <\/p>\n
In cases of very early or almost complete switching, the randomized control comparison may contain very little information for a hypothetical effect. The precision of an adjusted estimate then depends not only on the number of randomized individuals but also on the number and clinical comparability of the patients who are actually observed without switching. <\/p>\n
The RPSFT model assumes that the investigational therapy accelerates or decelerates individual disease time in a comparable manner, regardless of when it is started. Under this assumption, the model reconstructs a counterfactual survival time without exposure to the investigational therapy. Credibility depends in particular on whether a later start after progression can actually have the same effect relationship as an earlier treatment. <\/p>\n
IPCW artificially censors individuals at the time of switching and weights those who remain in the original arm until then so that they also represent the censored individuals. To do this, measured baseline and time-dependent factors must sufficiently explain the switch; otherwise, informative censoring remains. Two-stage procedures estimate the effect of the switch from a clinically defined secondary starting point, often after progression, and require plausible modeling of this time point and the prognostic factors. <\/p>\n
Treatment switching adjustment concerns a one-way switch permitted after progression in a parallel randomized trial. It is not to be equated with a planned crossover design or a crossover study, in which the treatment sequence itself is part of the randomized design and participants undergo multiple periods as planned. Here, the initial allocation remains in place, while only a portion of the control group utilizes a later therapy option. <\/p>\n
Furthermore, a switch is not a mere missing data problem. ICH E9(R1) treats it as an intercurrent event for which the clinical handling is determined in the estimand. In contrast, administrative censoring arises, for example, from the end of the study without an observed event. Although the adjustment models create artificial censoring or counterfactual times in the event of a switch, their justification lies in the pre-defined hypothetical question. <\/p>\n
Study teams must record the switching pathway with patient-level precision: the date of progression, decision criteria, start and duration of subsequent therapy, and time-dependent prognostic features determine whether an adjustment is possible. The SAP should clearly distinguish between the ITT effect and the additional hypothetical estimate, justify the chosen method, and provide for sensitivity analyses regarding its assumptions. Without sufficient variation in the actual switching pattern, weights in particular can become unstable or model assumptions cannot be reliably tested. <\/p>\n
The decision for an adjustment is therefore not made only when reading the survival curves. It requires a clinical justification for access to the investigational therapy in the control arm and a data collection concept that captures the prognostic situation immediately prior to the switch. <\/p>\n
Full-service CROs like Mediconomics support treatment switching adjustments by developing CRF fields for progression and subsequent therapy, specifying the hypothetical estimand, programming RPSFT, IPCW, or two-stage analyses, and ensuring the traceability of assumptions in the CSR. Medical Writing can present ITT and adjusted results separately so that the respective decision-making question remains recognizable. <\/p>\n
Does a switching adjustment replace the primary ITT analysis?<\/strong><\/p>\n No. The ITT analysis preserves the randomized comparison of the initial allocation. A switching adjustment only complements it if a second, hypothetical question regarding survival without later access to the investigational therapy is justified and methodologically plannable. <\/p>\n Why can’t you just censor at the time of switching?<\/strong><\/p>\n Those who switch after progression often have a different prognosis than patients who do not switch. Simple censoring assumes that these differences are irrelevant to subsequent survival. IPCW attempts to address this informative selection with measured factors but cannot compensate for unobserved causes. <\/p>\n When is a two-stage adjustment appropriate?<\/strong><\/p>\n It may be suitable when a clear secondary starting point, such as first progression, exists and the prognosis after this point can be modeled. If a clinically meaningful common starting point is missing, the procedure is usually less effective at addressing the question. <\/p>\n A treatment switching adjustment involves procedures used to estimate the effect of the originally randomized therapy on overall survival when individuals from the control group switch to the investigational therapy after progression. The intention-to-treat comparison remains valid for the effect of an allocation strategy, but it can attenuate the difference in overall survival because a […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[22],"class_list":["post-7806","glossary","type-glossary","status-publish","hentry","glossary-cat-biostatistik-methodik"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/7806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/7806\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=7806"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=7806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n